Tabula Rasa Ventures

Tabula Rasa Ventures is an investment firm specializing in healthcare and biotechnology, with a strong focus on psychedelic therapeutics. Founded in 2018, the firm seeks to fill critical gaps in the healthcare industry by investing in innovative startups across the biotech, drug development, and digital health sectors. Headquartered in New York, Tabula Rasa Ventures has become a leader in the psychedelic ecosystem, providing early-stage capital, incubation, and acceleration for groundbreaking ventures. The firm's investment strategy revolves around supporting startups from their inception through growth stages. They work hands-on with founders, offering deep expertise in scaling, regulatory affairs, and clinical trials. Tabula Rasa has built a diverse portfolio of companies like ATAI Life Sciences, Wavepaths, and Lykos Therapeutics, all of which are pushing the boundaries of mental health treatment and healthcare infrastructure. Led by Managing Partners Marik Hazan and Maria Velkova, Tabula Rasa Ventures takes a community-driven approach. They emphasize sustainable long-term growth by fostering trust among stakeholders, whether they are investors, patients, or regulators. With investments ranging from $50,000 to $1 million, the firm remains committed to transforming healthcare through cutting-edge solutions that address significant unmet needs in mental health and beyond. Their involvement in conferences such as the World Economic Forum.